

# Rheumatoid Arthritis (RA)- Market Insights, Epidemiology and Market Forecast 2028

<https://marketpublishers.com/r/R04CDF60C5EEN.html>

Date: June 2019

Pages: 101

Price: US\$ 5,980.00 (Single User License)

ID: R04CDF60C5EEN

## Abstracts

### REPORT SUMMARY

'Rheumatoid Arthritis (RA)- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering?

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

### Rheumatoid Arthritis (RA) Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Rheumatoid Arthritis (RA) in the US, Europe, and Japan are also provided in the report.

### Rheumatoid Arthritis (RA) Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies,

survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

#### Rheumatoid Arthritis (RA) Product Profiles & Analysis

This part of the Rheumatoid Arthritis (RA) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

#### Rheumatoid Arthritis (RA) Market Outlook

The Rheumatoid Arthritis (RA) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

#### Rheumatoid Arthritis (RA) Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

#### Rheumatoid Arthritis (RA) Report Insights

##### Patient Population in Rheumatoid Arthritis (RA)

##### Therapeutic Approaches in Rheumatoid Arthritis (RA)

##### Rheumatoid Arthritis (RA) Pipeline Analysis

Rheumatoid Arthritis (RA) Market Size and Trends  
Rheumatoid Arthritis (RA) Market Opportunities  
Impact of upcoming Therapies in Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA) Report Key Strengths  
10 Year Forecast  
7MM Coverage  
Epidemiology Segmentation  
Drugs Uptake  
Highly Analyzed Market  
Key Cross Competition

Rheumatoid Arthritis (RA) Report Assessment  
Current Treatment Practices in Rheumatoid Arthritis (RA)  
Unmet Needs in Rheumatoid Arthritis (RA)  
Detailed Rheumatoid Arthritis (RA) Pipeline Product Profiles  
Market Attractiveness  
Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Rheumatoid Arthritis (RA) market  
Organize sales and marketing efforts by identifying the best opportunities for Rheumatoid Arthritis (RA) market  
To understand the future market competition in the Rheumatoid Arthritis (RA) market.

**Note:** We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.  
Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Contents

### 1 KEY INSIGHTS

### 2 RHEUMATOID ARTHRITIS (RA) MARKET OVERVIEW AT A GLANCE

2.1 Market Share (%) Distribution of Rheumatoid Arthritis (RA) in 2018

2.2 Market Share (%) Distribution of Rheumatoid Arthritis (RA) in 2028

### 3 RHEUMATOID ARTHRITIS (RA): DISEASE BACKGROUND AND OVERVIEW

3.1 Introduction

3.2 Symptoms

3.3 Etiology

3.4 Risk Factor

3.5 Pathophysiology

3.6 Diagnosis

3.7 Treatment

### 4 EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Rheumatoid Arthritis (RA) in 7MM

4.3. Total Prevalent Patient Population of Rheumatoid Arthritis (RA) in 7MM – By Countries

### 5 EPIDEMIOLOGY OF RHEUMATOID ARTHRITIS (RA) BY COUNTRIES (2016-2028)

5.1 United States- Epidemiology (2016-2028)

5.1.1 Assumptions and Rationale

5.1.2 Prevalent/Incident Cases of Rheumatoid Arthritis (RA) in the United States

5.1.3 Sub-Type Specific cases of Rheumatoid Arthritis (RA) in the United States

5.1.4 Sex- Specific Cases of Rheumatoid Arthritis (RA) in the United States

5.1.5 Diagnosed Cases of Rheumatoid Arthritis (RA) in the United States

5.1.6 Treatable Cases of Rheumatoid Arthritis (RA) in the United States

5.2 EU5 Countries

5.2.1 Germany

5.2.1.1 Assumptions and Rationale

5.2.1.2 Prevalent/Incident Cases of the of Rheumatoid Arthritis (RA) in the Germany

5.2.1.3 Sub-Type Specific cases of Rheumatoid Arthritis (RA) in the Germany

5.2.1.4 Sex- Specific Cases of the Rheumatoid Arthritis (RA) in the Germany

5.2.1.5 Diagnosed Cases of the Rheumatoid Arthritis (RA) in the Germany

5.2.1.6 Treatable Cases of the Rheumatoid Arthritis (RA)

## 5.2.2 France

5.2.2.1 Assumptions and Rationale

5.2.2.2 Prevalent/Incident Cases of the of Rheumatoid Arthritis (RA) in the France

5.2.2.3 Sub-Type Specific cases of Rheumatoid Arthritis (RA) in the France

5.2.2.4 Sex- Specific Cases of the Rheumatoid Arthritis (RA) in the France

5.2.2.5 Diagnosed Cases of the Rheumatoid Arthritis (RA) in the France

5.2.2.6 Treatable Cases of the Rheumatoid Arthritis (RA)

## 5.2.3 Italy

5.2.3.1 Assumptions and Rationale

5.2.3.2 Prevalent/Incident Cases of the of Rheumatoid Arthritis (RA) in the Italy

5.2.3.3 Sub-Type Specific cases of Rheumatoid Arthritis (RA) in the Italy

5.2.3.4 Sex- Specific Cases of the Rheumatoid Arthritis (RA) in the Italy

5.2.3.5 Diagnosed Cases of the Rheumatoid Arthritis (RA) in the Italy

5.2.3.6 Treatable Cases of the Rheumatoid Arthritis (RA)

## 5.2.4 Spain

5.2.4.1 Assumptions and Rationale

5.2.4.2 Prevalent/Incident Cases of the of Rheumatoid Arthritis (RA) in the Spain

5.2.4.3 Sub-Type Specific cases of Rheumatoid Arthritis (RA) in the Spain

5.2.4.4 Sex- Specific Cases of the Rheumatoid Arthritis (RA) in the Spain

5.2.4.5 Diagnosed Cases of the Rheumatoid Arthritis (RA) in the Spain

5.2.4.6 Treatable Cases of the Rheumatoid Arthritis (RA)

## 5.2.5 United Kingdom

5.2.5.1 Assumptions and Rationale

5.2.5.2 Prevalent/Incident Cases of the of Rheumatoid Arthritis (RA) in the United Kingdom

5.2.5.3 Sub-Type Specific cases of Rheumatoid Arthritis (RA) in the United Kingdom

5.2.5.4 Sex- Specific Cases of the Rheumatoid Arthritis (RA) in the United Kingdom

5.2.5.5 Diagnosed Cases of the Rheumatoid Arthritis (RA) in the United Kingdom

5.2.5.6 Treatable Cases of the Rheumatoid Arthritis (RA)

## 5.3 Japan

5.3.1 Assumptions and Rationale

5.3.2 Prevalent/Incident Cases of the of Rheumatoid Arthritis (RA) in the Japan

5.3.3 Sub-Type Specific cases of Rheumatoid Arthritis (RA) in the Japan

5.3.4 Sex- Specific Cases of the Rheumatoid Arthritis (RA) in the Japan

5.3.5 Diagnosed Cases of the Rheumatoid Arthritis (RA) in the Japan

### 5.3.6 Treatable Cases of the Rheumatoid Arthritis (RA)

## **6 CURRENT TREATMENT & MEDICAL PRACTICES**

### 6.1 Treatment Algorithm

### 6.2 Treatment Guidelines

## **7 UNMET NEEDS**

## **8 MARKETED PRODUCT**

### 8.1 Drug A: Company

#### 8.1.1 Drug Description

#### 8.1.2 Mechanism of Action

#### 8.1.3 Clinical Trials Details

#### 8.1.4 Advantages & Disadvantages

#### 8.1.5 Safety and Efficacy

#### 8.1.6 Product Profile

### 8.2 Drug B: Company

#### 8.2.1 Drug Description

#### 8.2.2 Mechanism of Action

#### 8.2.3 Clinical Trials Details

#### 8.2.4 Advantages & Disadvantages

#### 8.2.5 Safety and Efficacy

#### 8.2.6 Product Profile

### 8.3 Drug C: Company

#### 8.3.1 Drug Description

#### 8.3.2 Mechanism of Action

#### 8.3.3 Clinical Trials Details

#### 8.3.4 Advantages & Disadvantages

#### 8.3.5 Safety and Efficacy

#### 8.3.6 Product Profile

### 8.4 Drug D: Company

#### 8.4.1 Drug Description

#### 8.4.2 Mechanism of Action

#### 8.4.3 Clinical Trials Details

#### 8.4.4 Advantages & Disadvantages

#### 8.4.5 Safety and Efficacy

#### 8.4.6 Product Profile

## 8.5 Drug E: Company

### 8.5.1 Drug Description

### 8.5.2 Mechanism of Action

### 8.5.3 Clinical Trials Details

### 8.5.4 Advantages & Disadvantages

### 8.5.5 Safety and Efficacy

### 8.5.6 Product Profile

## 8.6 : Company

### 8.6.1 Drug Description

### 8.6.2 Mechanism of Action

### 8.6.3 Clinical Trials Details

### 8.6.4 Advantages & Disadvantages

### 8.6.5 Safety and Efficacy

### 8.6.6 Product Profile

## 8.7 : Company

### 8.7.1 Drug Description

### 8.7.2 Mechanism of Action

### 8.7.3 Clinical Trials Details

### 8.7.4 Advantages & Disadvantages

### 8.7.5 Safety and Efficacy

### 8.7.6 Product Profile

## 8.8 : Company

### 8.8.1 Drug Description

### 8.8.2 Mechanism of Action

### 8.8.3 Clinical Trials Details

### 8.8.4 Advantages & Disadvantages

### 8.8.5 Safety and Efficacy

### 8.8.6 Product Profile

## 9 EMERGING DRUGS

### 9.1 Key Cross Competition

### 9.2 Emerging company

#### 9.2.1 Emerging Drug A: Company

##### 9.2.1.1 Other Development Activities

##### 9.2.1.2 Clinical Development

##### 9.2.1.3 Clinical Trials Information

##### 9.2.1.4 Safety and Efficacy

##### 9.2.1.5 Advantages and Disadvantages

- 9.2.1.6 Product Profile
- 9.2.2 Emerging Drug B: Company
  - 9.2.2.1 Other Development Activities
  - 9.2.2.2 Clinical Development
  - 9.2.2.3 Clinical Trials Information
  - 9.2.2.4 Safety and Efficacy
  - 9.2.2.5 Advantages and Disadvantages
  - 9.2.2.6 Product Profile
- 9.2.3 Emerging Drug C: Company
  - 9.2.3.1 Other Development Activities
  - 9.2.3.2 Clinical Development
  - 9.2.3.3 Clinical Trials Information
  - 9.2.3.4 Safety and Efficacy
  - 9.2.3.5 Advantages and Disadvantages
  - 9.2.3.6 Product Profile
- 9.2.4 Emerging Drug D: Company
  - 9.2.4.1 Other Development Activities
  - 9.2.4.2 Clinical Development
  - 9.2.4.3 Clinical Trials Information
  - 9.2.4.4 Safety and Efficacy
  - 9.2.4.5 Advantages and Disadvantages
  - 9.2.4.6 Product Profile
- 9.2.5 Emerging Drug E: Company
  - 9.2.5.1 Other Development Activities
  - 9.2.5.2 Clinical Development
  - 9.2.5.3 Clinical Trials Information
  - 9.2.5.4 Safety and Efficacy
  - 9.2.5.5 Advantages and Disadvantages
  - 9.2.5.6 Product Profile

## **10 7MM MARKET ANALYSIS**

- 10.1 7MM Market Size of Rheumatoid Arthritis (RA)
- 10.2 7MM Percentage Share of Drugs Marketed for Rheumatoid Arthritis (RA)
- 10.3 7MM Market Sales of Rheumatoid Arthritis (RA) by Products

## **11 THE UNITED STATES MARKET OUTLOOK**

- 11.1 Market Size of Rheumatoid Arthritis (RA) in United States

11.2 Percentage Share of Drugs Marketed for Rheumatoid Arthritis (RA) in United States

11.3 Market Sales of Rheumatoid Arthritis (RA) by Products in United States

11.4 Analysis of Upcoming Therapies and Impact on the Market

## **12 EU5 COUNTRIES MARKET OUTLOOK**

12.1 Market Size of Rheumatoid Arthritis (RA) in EU5

12.2 Market Size of Rheumatoid Arthritis (RA) in Germany

12.2.1 Market Size of Rheumatoid Arthritis (RA) in Germany

12.2.2 Percentage Share of Drugs Marketed for Rheumatoid Arthritis (RA) in Germany

12.2.3 Market Sales of Rheumatoid Arthritis (RA) by Products in Germany

12.2.4 Analysis of Upcoming Therapies and Impact on the Market

12.3 Market Size of Rheumatoid Arthritis (RA) in France

12.3.1 Market Size of Rheumatoid Arthritis (RA) in France

12.3.2 Percentage Share of Drugs Marketed for Rheumatoid Arthritis (RA) in France

12.3.3 Market Sales of Rheumatoid Arthritis (RA) by Products in France

12.3.4 Analysis of Upcoming Therapies and Impact on the Market

12.4 Market Size of Rheumatoid Arthritis (RA) in Italy

12.4.1 Market Size of Rheumatoid Arthritis (RA) in Italy

12.4.2 Percentage Share of Drugs Marketed for Rheumatoid Arthritis (RA) in Italy

12.4.3 Market Sales of Rheumatoid Arthritis (RA) by Products in Italy

12.4.4 Analysis of Upcoming Therapies and Impact on the Market

12.5 Market Size of Rheumatoid Arthritis (RA) in Spain

12.5.1 Market Size of Rheumatoid Arthritis (RA) in Spain

12.5.2 Percentage Share of Drugs Marketed for Rheumatoid Arthritis (RA) in Spain

12.5.3 Market Sales of Rheumatoid Arthritis (RA) by Products in Spain

12.5.4 Analysis of Upcoming Therapies and Impact on the Market

12.6 Market Size of Rheumatoid Arthritis (RA) in United Kingdom

12.6.1 Market Size of Rheumatoid Arthritis (RA) in United Kingdom

12.6.2 Percentage Share of Drugs Marketed for Rheumatoid Arthritis (RA) in United Kingdom

12.6.3 Market Sales of Rheumatoid Arthritis (RA) by Products in United Kingdom

12.6.4 Analysis of Upcoming Therapies and Impact on the Market

## **13 THE JAPAN MARKET OUTLOOK**

13.1 Market Size of Rheumatoid Arthritis (RA) in Japan

13.2 Percentage Share of Drugs Marketed for Rheumatoid Arthritis (RA) in Japan

13.3 Market Sales of Rheumatoid Arthritis (RA) by Products in Japan

13.4 Analysis of Upcoming Therapies and Impact on the Market

## **14 COST ANALYSIS OF RHEUMATOID ARTHRITIS (RA)**

## **15 GENERIC COMPETITION IN RHEUMATOID ARTHRITIS (RA) MARKET**

## **16 MARKET DRIVERS**

## **17 MARKET BARRIERS**

## **18 REPORT METHODOLOGY**

18.1 Methodology/Research Approach

18.2 Data Source

18.2.1 Secondary Sources

18.2.2 Primary Sources

## I would like to order

Product name: Rheumatoid Arthritis (RA)- Market Insights, Epidemiology and Market Forecast 2028

Product link: <https://marketpublishers.com/r/R04CDF60C5EEN.html>

Price: US\$ 5,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R04CDF60C5EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970